Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine with propofol or ciprofol for MECT in major depressive disorder (EPC-MDD)
ChiCTR2400083664Phase 4Not yet recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in major depressive disorder (MDD) (4 arms), sponsored by Renmin Hospital of Wuhan University. Primary endpoint: Change in HAMD-24 total score. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2400083664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083664.